News

The Native Antigen Company introduces new range of influenza antigens

0

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

Gene signature quickly predicts who’ll develop vaccine immunity

Previous article

New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in News